Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Conmed (CNMD) EBITDA Margin (2016 - 2025)

Conmed's EBITDA Margin history spans 16 years, with the latest figure at 5.27% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 329.0% year-over-year to 5.27%; the TTM value through Dec 2025 reached 4.34%, down 513.0%, while the annual FY2025 figure was 4.34%, 513.0% down from the prior year.
  • EBITDA Margin reached 5.27% in Q4 2025 per CNMD's latest filing, up from 1.95% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 15.68% in Q3 2022 to a low of 62.28% in Q2 2022.
  • Average EBITDA Margin over 5 years is 3.87%, with a median of 6.6% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: tumbled -6923bps in 2022, then skyrocketed 6724bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 10.87% in 2021, then grew by 6bps to 11.5% in 2022, then dropped by -2bps to 11.27% in 2023, then fell by -24bps to 8.56% in 2024, then tumbled by -38bps to 5.27% in 2025.
  • Per Business Quant, the three most recent readings for CNMD's EBITDA Margin are 5.27% (Q4 2025), 1.95% (Q3 2025), and 7.55% (Q2 2025).